Surgery for Treatment of Recurrent Ovarian Cancer
Links shared publicly online about this topic
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA
oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 7, 2010 at 8:20 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer http://goo.gl/fb/vAkMj
Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR
empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.” View full resource at empr.com
Most Recently Shared on June 7, 2010 at 8:14 pm By:
MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj
Drug-Treatment Opportunities In Advanced Ovarian Cancer Will Be Limited By A Reduced Risk Of Disease Recurrence
medicalnewstoday.com — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that projected improvements in recurrence-free survival and an only modes” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2010 at 6:05 pm By:
MNT Ovarian Cancer Health News
Drug-Treatment Opportunities In Advanced Ovarian Cancer Will Be Limited By A Reduced Risk Of Disease Recurrence http://mnt.to/3NP9
Ovarian Cancer: eMedicine Oncology
emedicine.medscape.com — “Overview: Ovarian cancer is the most common cause of cancer death from gynecologic tumors in the United States. Early disease causes minimal, nonspecific, or no symptoms. Therefore, most cases are diagnosed in an advanced stage. Overall, prognosis ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 12, 2010 at 6:04 pm By:
Medscape Oncology Oncology and Health Site
Ovarian Cancer: Study finds cytoreductive surgery safe and effective in platinum-sensitive recurrent ovarian cancer. http://bit.ly/9ZmUBA
Detecting breast cancer recurrence
physorg.com — “Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain and ovarian cancer before succumbing to the disease in their early ...” View full resource at physorg.com
Most Recently Shared on October 20, 2010 at 3:12 pm By:
Detecting breast cancer recurrence http://bit.ly/9do9jO
ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer
news-medical.net — “A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG).” View full resource at news-medical.net
Most Recently Shared on June 4, 2010 at 9:26 am By:
ChemoFx-assisted chemotherapy reduces treatment costs for recurrent ovarian cancer: A study demonstrating the cost... http://bit.ly/bn3YeK
Oncology Article | ovarian cancer
mdlinx.com — “Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort” View full resource at mdlinx.com
Most Recently Shared on September 1, 2011 at 10:32 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive su... http://t.co/VTK4Upu #oncology
Oncology Article | ovarian cancer
mdlinx.com — “Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort” View full resource at mdlinx.com
Most Recently Shared on September 2, 2011 at 5:09 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Dr RY Zang just commented on: Predictors of survival in patients with recurrent ovarian cancer under... http://t.co/oeXOK6i #authorcmnt
Ovarian Cancer: Gynecologist Disputes Findings
medicalnewstoday.com — “An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer” View full resource at medicalnewstoday.com
Most Recently Shared on October 18, 2010 at 1:05 pm By:
MNT Clinical Trials Health News
Ovarian Cancer: Gynecologist Disputes Findings http://mnt.to/3Lm8 #clinicaltrials
Medical News: ASCO: Trabectedin Useful in Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Trabectedin may have a role in the treatment of recurrent ovarian cancer while sparing patients for a time from platinum-based regimens, according to several studies presented here.” View full resource at medpagetoday.com
Most Recently Shared on June 8, 2010 at 5:51 pm By:
ASCO: Trabectedin Useful in Recurrent Ovarian Cancer http://bit.ly/cdzGwZ
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
blog.mdlinx.com — “The findings of this study are opposite to what would be expected if these markers were good surrogates for treatment benefit.” View full resource at blog.mdlinx.com
Most Recently Shared on August 15, 2011 at 9:51 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer http://t.co/4Kziuul
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer - Drugs.com MedNews
drugs.com — “THOUSAND OAKS, Calif., Amgen (Nasdaq AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial invo” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer: THOU... http://bit.ly/b2PL9F #drug
New treatment shows promise against recurrent gynecologic cancers
physorg.com — “(BRONX, NY) - Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo. Now, physicians ...” View full resource at physorg.com
Most Recently Shared on April 21, 2009 at 11:55 pm By:
New treatment shows promise against recurrent gynecologic cancers http://tinyurl.com/cgnpe9
Arch Dermatol -- Abstract: Panniculitis Associated With Dermatomyositis and Recurrent Ovarian Cancer, March 19, 2012, Girouard et al. 0 (2012): archdermatol.2012.288v1
archderm.ama-assn.org — “Archives of Dermatology is a monthly professional medical journal published by the American Medical Association. Archives of Dermatology publishes original, peer-reviewed reports and discussions that address the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery” View full resource at archderm.ama-assn.org
Most Recently Shared on March 20, 2012 at 12:41 pm By:
Panniculitis Associated With Dermatomyositis and Recurrent Ovarian Cancer [Observation]: Conclusions Although p... http://t.co/Uc8Yiazv
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer - QualityPoint Technologies
qualitypointtech.net — “CHICAGO (MedPage Today) -- Treatment with an investigational DNA repair inhibitor almost doubled progression-free survival in patients with relapsed, platinum-sensitive ovarian cancer, data from a randomized trial showed.” View full resource at qualitypointtech.net
Most Recently Shared on May 18, 2011 at 11:45 pm By:
ASCO: PARP Inhibitor Slows Recurrent Ovarian Cancer: CHICAGO (MedPage Today) -- Treatment with an investigational ... http://bit.ly/kWiXXK
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MNT Ovarian Cancer
The latest ovarian cancer news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
